Moderna
MRNA
1,109 hedge funds and large institutions have $62.5B invested in Moderna in 2021 Q4 according to their latest regulatory filings, with 221 funds opening new positions, 402 increasing their positions, 380 reducing their positions, and 233 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 402 | Existing positions reduced: 380
0.55% more ownership
Funds ownership: 60.25% → 60.81% (+0.55%)
5% less first-time investments, than exits
New positions opened: 221 | Existing positions closed: 233
3% less funds holding
Funds holding: 1,141 → 1,109 (-32)
25% less call options, than puts
Call options by funds: $5.54B | Put options by funds: $7.37B
33% less capital invested
Capital invested by funds: $93.5B → $62.5B (-$31B)
44% less funds holding in top 10
Funds holding in top 10: 39 → 22 (-17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.04B |
| 2 |
Barclays
London,
United Kingdom
|
+$599M |
| 3 |
TP
Theleme Partners
London,
United Kingdom
|
+$311M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$276M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$267M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$1.28B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$924M |
| 3 |
Coatue Management
New York
|
-$515M |
| 4 |
Morgan Stanley
New York
|
-$240M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$215M |
MRNA Hedge Fund Activity: Q4 2021 in Review
1,109 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q4 2021, worth a combined $62.5B — down 33% from $93.5B a quarter earlier.
Sellers outnumbered buyers: 233 funds closed out of MRNA and 221 opened new positions — a net loss of 12 holders — while 380 trimmed existing stakes and 402 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $1.04B. The largest seller was Lone Pine Capital, exiting entirely with an estimated $1.28B sold.
- 1,109 institutional investors held Moderna (MRNA) as of Q4 2021, down from 1,141 in Q3 2021.
- Funds reported $62.5B of Moderna stock for Q4 2021, down 33% quarter-over-quarter.
- 221 funds opened new Moderna positions in Q4 2021 and 233 closed out, a net change of -12 holders.
- The largest Moderna buyer in Q4 2021 was Baillie Gifford & Co, an estimated $1.04B added.
- The largest Moderna seller in Q4 2021 was Lone Pine Capital, an estimated $1.28B sold.
Based on aggregated 13F filings for Q4 2021.